France has canceled its order for Merck’s new Covid-19 antiviral remedy molnupiravir because of its weak efficiency in trials, and ordered Pfizer’s Paxlovid as a substitute, Well being Minister Olivier Veran mentioned on Wednesday.
“With molnupiravir, we needed to cancel the order,” Veran advised BFMTV, explaining that the newest trial outcomes of Merck’s remedy have been “not good.” The cancellation of the 50,000 doses of the drug has incurred no prices to France, he pressured.
As an alternative of Merck’s tablets, France has ordered a competing remedy, Pfizer’s Paxlovid, which Veran described as “extraordinarily promising” in lowering the danger of creating severe types of Covid-19. The minister mentioned that the drug, which is awaiting approval by the European Medicines Company, would turn into obtainable by the tip of January.
He didn’t specify what number of doses of Paxlovid had been ordered.
Merck earlier reported that its tablets diminished the danger of hospitalization and deaths by 30%, which is considerably much less spectacular than the 89% discount reported by Pfizer.
France is the primary nation to announce cancellation of its Merck order. The UK and German governments are amongst people who have already purchased doses of the drug.